Follicular Lymphoma: Hard to Improve on Bendamustine/Rituximab Induction

The latest data from the three-arm randomized phase 2 ECOG-ACRIN E2408 trial, which sought to improve upon frontline bendamustine/rituximab (BR) induction therapy followed by rituximab maintenance in untreated high-risk follicular lymphoma (FL), have yielded disappointing results: neither adding bortezomib to BR induction nor adding lenalidomide following BR induction improves outcomes. For the trial, 289 patients were randomized to receive either BR induction followed by two-year rituximab main...
Continue reading

Tazemetostat for Follicular Lymphoma Granted Accelerated Approval

Tazemetostat (TAZVERIK™, Epizyme, Inc.) has been approved for adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) who have tumors that are positive for an EZH2 mutation, have received at least 2 previous systemic therapies, and have no satisfactory alternative treatment options. In addition, the FDA approved the cobas® EZH2 Mutation Test (Roche Molecular Systems, Inc.) as a companion diagnostic for tazemetostat. An EZH2 inhibitor, tazemetostat has previously been approved f...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.